Recent studies have demonstrated that several systemic inflammation biomarkers, such as neutrophil-lymphocyte ratio, C-reactive protein (CRP)-albumin ratio, platelet-lymphocyte ratio, were acting as predictors of prognosis in several types of malignant tumors, including CRC [5,7–9]. This evidence concerns the gene CRP and cancer.